Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

sarilumab phase 2 high dose unpublished
 
NCT04315298
RCTsarilumab high dose (400mg)placeboCOVID 19 all comershigh
145/77 suggested
  • suggested 61 % decrease in death or ventilation but with a low degree of certainty due to high risk of bias
  • suggested 73 % decrease in ventilation but with a low degree of certainty due to high risk of bias
there were negative trends for most outcomes in the “severe” group, while there were positive trends for all outcomes in the “critical” group
sarimulab phase 2 low dose unpublished
 
NCT04315298
RCTsarilumab low dose (200mg)placeboCOVID 19 all comershigh
136/77 suggested
  • suggested 72 % decrease in ventilation but with a low degree of certainty due to high risk of bias
there were negative trends for most outcomes in the “severe” group, while there were positive trends for all outcomes in the “critical” group

COVID-19 severe or critically meta-analysis

REMAP-CAP sarilumab, 2021
 
NCT02735707
RCTsarilumabstandard of careCOVID-19 severe or criticallysome concern
48/402 conclusif
  • demonstrated 76 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
ARI-RAF (Della-Torre), 2020 OBSsarilumabcontrolCOVID-19 severe or criticallyNA
28/28 inconclusive

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).